Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$5.78 -0.6%	$4.70	$1.14 ▼ $7.20	$345.92M	0.76	1.19 million shs	475,353 shs
IMAB I-Mab	$4.89 -4.0%	$2.81	$0.60 ▼ $5.90	$398.91M	1.38	948,044 shs	1.82 million shs
INBX Inhibrx Biosciences	$25.00	$20.30	$10.81 ▼ $25.61	$362M	0.24	106,024 shs	54,622 shs
OKYO OKYO Pharma	$2.42 +1.9%	$2.70	$0.90 ▼ $3.35	$90.83M	-0.09	172,688 shs	108,833 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	+7.79%	+12.38%	+161.71%	+4.31%
IMAB I-Mab	0.00%	+4.52%	+141.23%	+414.14%	+318.93%
INBX Inhibrx Biosciences	0.00%	+7.16%	+8.32%	+94.40%	+87.41%
OKYO OKYO Pharma	0.00%	-10.57%	-13.82%	+28.11%	+127.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	1.8471 of 5 stars	3.3	1.0	0.0	1.9	1.7	0.6
IMAB I-Mab	3.2902 of 5 stars	3.7	5.0	0.0	3.2	1.7	0.0
INBX Inhibrx Biosciences	1.3783 of 5 stars	0.0	3.0	4.6	2.0	1.7	0.0
OKYO OKYO Pharma	2.4146 of 5 stars	3.5	5.0	0.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.67	Moderate Buy	$9.50	64.50% Upside
IMAB I-Mab	3.33	Buy	$6.50	33.06% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
OKYO OKYO Pharma	3.00	Buy	$7.00	189.86% Upside

Current Analyst Ratings Breakdown

Latest OKYO, IMAB, ALDX, and INBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/21/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/20/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $6.00
8/8/2025	ALDX Aldeyra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/9/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
IMAB I-Mab	$3.89M	102.55	N/A	N/A	$2.47 per share	1.98
INBX Inhibrx Biosciences	$200K	1,810.00	$119.05 per share	0.21	$9.23 per share	2.71
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.85	N/A	N/A	N/A	N/A	-73.63%	-50.61%	11/6/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.65%	-18.58%	11/13/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	-$10.58	N/A	N/A	N/A	N/A	-137.83%	-76.31%	11/13/2025 (Estimated)
OKYO OKYO Pharma	-$4.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest OKYO, IMAB, ALDX, and INBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2025	IMAB I-Mab	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
8/13/2025	Q2 2025	INBX Inhibrx Biosciences	-$2.92	-$1.85	+$1.07	-$1.85	N/A	$1.30 million
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.21	-$0.16	+$0.05	-$0.16	$1.08 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.86	2.86
IMAB I-Mab	N/A	22.82	22.82
INBX Inhibrx Biosciences	1.45	4.98	4.98
OKYO OKYO Pharma	N/A	0.40	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
IMAB I-Mab	38.38%
INBX Inhibrx Biosciences	82.46%
OKYO OKYO Pharma	2.97%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	8.50%
IMAB I-Mab	22.10%
INBX Inhibrx Biosciences	N/A
OKYO OKYO Pharma	40.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.81 million	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
INBX Inhibrx Biosciences	166	14.48 million	N/A	Optionable
OKYO OKYO Pharma	7	37.61 million	22.39 million	Not Optionable

OKYO, IMAB, ALDX, and INBX Headlines

Recent News About These Companies

OKYO Pharma (NASDAQ:OKYO) Raised to "Hold" at Wall Street Zen

August 10, 2025 | marketbeat.com

Neuropathic corneal pain reduced in phase 2 trial of urcosimod

August 7, 2025 | healio.comH

Dauntless Investment Group LLC Invests $2.53 Million in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO)

July 29, 2025 | marketbeat.com

OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI

July 19, 2025 | proactiveinvestors.com

OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI

July 19, 2025 | proactiveinvestors.com

OKYO Slides Despite Fresh R&D Funding

July 17, 2025 | baystreet.ca

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

July 17, 2025 | finance.yahoo.com

OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development

July 17, 2025 | tipranks.com

OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy

July 17, 2025 | proactiveinvestors.com

OKYO reports top-line data from neuropathic corneal pain therapy trial

July 17, 2025 | finance.yahoo.com

Okyo sets sights on first approval in neuropathic eye pain after phase 2 win

July 16, 2025 | fiercebiotech.comF

OKYO Pharma shares surge following promising Phase 2 data for eye pain treatment

July 16, 2025 | msn.com

Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation

July 16, 2025 | tipranks.com

OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain

July 16, 2025 | tipranks.com

OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain

July 16, 2025 | proactiveinvestors.com

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

July 16, 2025 | globenewswire.com

OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders

June 14, 2025 | uk.finance.yahoo.com

OKYO Pharma to Present at the Bio International Convention

June 11, 2025 | manilatimes.netM

OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts

June 11, 2025 | proactiveinvestors.com

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | OKYO Stock News

June 11, 2025 | gurufocus.com

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

June 11, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO, IMAB, ALDX, and INBX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$5.78 -0.04 (-0.60%)

Closing price 03:59 PM Eastern

Extended Trading

$5.76 -0.01 (-0.17%)

As of 04:04 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

I-Mab NASDAQ:IMAB

$4.88 -0.21 (-4.03%)

Closing price 03:59 PM Eastern

Extended Trading

$4.92 +0.03 (+0.61%)

As of 04:04 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Inhibrx Biosciences NASDAQ:INBX

$25.00 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$25.02 +0.02 (+0.08%)

As of 04:01 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

OKYO Pharma NASDAQ:OKYO

$2.42 +0.05 (+1.90%)

Closing price 03:57 PM Eastern

Extended Trading

$2.44 +0.02 (+1.04%)

As of 04:04 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time